An analysis of Leukapheresis as a prophylactic modality of therapy for ‘Tumor Lysis Syndrome’ compared to conventional management alone: A pilot open labelled Randomized control trial
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]Health Condition 2: C925- Acute myelomonocytic leukemiaHealth Condition 3: C92Z- Other myeloid leukemia
- Registration Number
- CTRI/2023/03/050636
- Lead Sponsor
- All India Institute of Medical Sciences Raipur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Leukapheresis for Hyperleukocytosis defined as Acute Myeloid leukemia on peripheral smear (PS) with WBC >100X109/l or Acute Lymphoblastic leukemia on PS with WBC >100X109/l or transformation of Chronic leukaemia with Blast count >20% (WBC >100X109/l) TLS Prophylaxis of AML/ALL with WBC <100,000/cumm & ? 25,000/ µl with prechemotherapy LDH ?2 X (times) upper limit of normal value categorised as intermediate risk TLS.
The Exclusion criteria for the Treatment are as follows:
i.Patients with clinical and Blood smear diagnosis other than Acute myeloid leukemia; Acute lymphoblastic leukemia or chronic leukemia with blast transformation classified a high or moderate risk TLS as mentioned in the inclusion criteria
ii.Patient with Acute myeloid Leukemia (Promyelocytic FAB M3) on peripheral smear.
iii.Unconscious or delirious patients who cannot provide a videographic consent.
iv.Ongoing tumor lysis syndrome for prophylactic Leukapheresis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method